- Rh-Apo2L Awarded Gold Medal in 20th Annual Invention Competition in Shanghai - HANGZHOU, China, Oct. 5 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC:AIDA) (BULLETIN BOARD: AIDA) , one of mainland China's leading pharmaceutical companies, today announced that the Company has received a Gold Metal in the 20th Annual Invention Competition of Shanghai for its revolutionary genetic cancer treatment, Rh-Apo2L, currently under development by Aida's subsidiary, Shanghai Qiaer Biotechnology. The 20th Annual Invention Competition is sponsored by Shanghai Intellectual Property Administration, Shanghai Hi-Tech Service Center, a government agency, and Jie Fang Daily, the largest daily newspaper in Shanghai. The goal of the Invention Competition is to find, acknowledge and reward new inventions, patents or technological advances which the committee of judges deems pioneering and uniquely useful with the potential to benefit a large portion of Chinese society. Mr. Zhou Jingsong, Chief Executive Officer of Shanghai Qiaer Biotechnology stated, "We are very proud of this accomplishment. This prestigious award shows the intrinsic value of Rh-Apo2L and the future promise that we believe the drug presents to cancer patients in China. Our genetic therapy, upon receiving all relevant government approvals, has the potential to help millions of cancer patients, and this award encourages us to steadfastly pursue what we believe will be the inevitable development and commercialization of Rh-Apo2L." Mr. Jin Biao, Chairman of Aida Pharmaceuticals and Shanghai Qiaer Biotechnology stated, "This award serves as affirmation that Aida is on track in researching, developing and bringing to market genetic therapies for the treatment of major diseases. We believe the biotechnology market in China is virtually untapped and still in its infancy. Aida intends to pursue the research and development of genetic therapies to penetrate this market and bring the Chinese people some of the most advanced treatments available in the world. Our current drug pipeline is focused on biotechnology and genetic therapies and we will continuously look into new therapies and partnerships, both locally and globally, to further strengthen our market position and diversify our already dynamic list of drugs in development." About Aida Pharmaceuticals: Aida Pharmaceuticals is a product-focused pharmaceuticals company engaged in the formulation, clinical testing, registration, manufacture, sales and marketing of advanced pharmaceutical and genetic products in mainland China. The Company's mission is to discover, develop and market meaningful new therapies that improve human health. Aida Pharmaceuticals, in operation since March 1999, is headquartered in Hangzhou, China with manufacturing, distribution and sales points throughout mainland China. Aida is GMP certified in China and ISO9002 certified for quality assurance and ISO14000 certified for ecologically-friendly practices. Aida is now producing and marketing a patented prescription drug in China: Etimicin Sulfate. It is the first antibiotic developed in China and is regarded as a category "A" drug by the State Food and Drug Administration of China. Contact Information: Company: Aida Pharmaceuticals, Inc. 31 Dingjiang Road Jianggan District Hangzhou, China 310016 Investor Relations: Equity Performance Group Gary Geraci (617) 723-2373 http://www.equityperformancegroup.com/ Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This press release includes certain "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995. These statements are based on Aida Pharmaceuticals, Inc.'s management's current expectations and are subject to risks and uncertainties and changes in circumstances. All forward-looking statements included in this press release are based upon information available to Aida Pharmaceuticals, Inc. as of the date of the press release, and it assumes no obligation to update or alter its forward looking statements whether as a result of new information, future events or otherwise. These forward-looking statements may relate to, among other things, plans and timing for the introduction or enhancement of our services and products, clinical trial results, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact. Further information on risks or other factors that could affect Aida Pharmaceuticals, Inc.'s results of operations is detailed in its filings with the United States Securities and Exchange Commission available at http://www.sec.gov/. DATASOURCE: Aida Pharmaceuticals, Inc. CONTACT: Investor Relations: Gary Geraci of Equity Performance Group, +1-617-723-2373, Web site: http://www.equityperformancegroup.com/

Copyright